+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Methicillin-Resistant Staphylococcus Aureus Drugs Market - Global Forecast 2026-2032- Product Image
Methicillin-Resistant Staphylococcus Aureus Drugs Market - Global Forecast 2026-2032- Product Image
New

Methicillin-Resistant Staphylococcus Aureus Drugs Market - Global Forecast 2026-2032

  • PDF Icon

    Report

  • 197 Pages
  • January 2026
  • Region: Global
  • 360iResearch™
  • ID: 4968650
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The Methicillin-Resistant Staphylococcus Aureus Drugs Market is experiencing accelerated change as new therapeutics, regulatory expectations, and supply chain factors shape how senior decision-makers approach procurement and long-term access. Leaders are prioritizing both clinical and operational resilience for a sustained value proposition.

Market Snapshot: MRSA Drugs Market Size, Growth, and Dynamics

The MRSA drugs market is projected to expand from USD 2.33 billion in 2025 to USD 2.47 billion in 2026, ultimately reaching USD 3.44 billion by 2032. This represents a CAGR of 5.70%. Market growth is driven by rising antibiotic resistance, advancements in drug innovation, and a measurable shift toward value-based and outpatient care. As these factors drive change, healthcare organizations, payers, and manufacturers are refining their strategies to align with stewardship imperatives and adapt to evolving global regulatory conditions. Suppliers are adjusting procurement models and investments to meet diverse market access requirements across regions.

Scope & Segmentation of the MRSA Therapeutics Market

This report provides actionable segmentation and regional context to support commercial, procurement, and clinical strategy development:

  • Administration Routes: Covers both intravenous and oral therapies, which influence clinical workflows, treatment adherence, and operational planning for hospitals and ambulatory settings.
  • Patient Types: Includes inpatients and outpatients, impacting access, reimbursement processes, and allocation of resources for safe and efficient MRSA care delivery.
  • Drug Classes: Encompasses multiple therapeutic categories, such as Cephalosporins (e.g., Ceftaroline), Glycopeptides (including Teicoplanin and Vancomycin), Lipopeptides (with Daptomycin), Oxazolidinones (such as Linezolid and Tedizolid), and Tetracyclines (covering Eravacycline and Tigecycline). Each class is evaluated for application settings, opportunity for therapy substitution, and known safety profiles.
  • Distribution Channels: Includes hospital pharmacies, online pharmacies, and retail outlets, each of which plays a critical role in procurement planning and distribution efficiency across geographies.
  • Regions: Analyzes the Americas, Europe, Middle East & Africa, and Asia-Pacific, acknowledging the unique regulatory climates and procurement frameworks affecting integration and localized market strategy.

Key Takeaways from MRSA Market Research

  • Manufacturers and healthcare providers must implement flexible strategies to adapt to evolving stewardship priorities and demonstrate consistent clinical value in response to changing treatment guidelines.
  • Outpatient antimicrobial therapy trends are reshaping care by driving the development of treatments that shorten hospital stays and support safer community-based management.
  • Payer requirements have shifted toward comprehensive cost-of-care frameworks, raising expectations for therapies that reduce overall expenses, including those linked to administration and post-treatment outcomes.
  • Competitive differentiation now depends on investment in real-world evidence and comparative effectiveness, which increasingly guide product positioning and inclusion decisions within formularies.
  • Regional regulatory dynamics and infrastructure remain essential factors in determining adoption timelines and market entry success, highlighting the need for local partnerships and tailored strategies.
  • Integrating technology, such as digital stewardship tools and remote patient monitoring, enables organizations to support compliance, enhance operational efficiency, and ensure care continuity across the healthcare system.

Tariff Impact: Navigating Cost and Supply Resilience

The introduction of new tariff policies in 2025 has increased cost variability across the MRSA therapeutic supply chain. Industry leaders are taking decisive actions to adjust:

  • Accelerating the development of onshore and nearshore manufacturing capabilities to minimize import dependency and mitigate volatility.
  • Re-negotiating supplier contracts to stabilize pricing structures and expand sourcing flexibility across multiple regions and channels.
  • Implementing sophisticated inventory management to maintain uninterrupted access for both hospital and community-based providers.
  • Leveraging value-based contracting approaches that connect medical pricing to broader care delivery objectives, improving cost predictability and alignment with payer priorities.

These initiatives underscore the necessity of robust procurement planning and adaptable sourcing in order to sustain supply reliability while managing exposure to fluctuating care costs.

Methodology & Data Sources

This analysis integrates structured interviews with clinical and procurement leaders, alongside a thorough review of peer-reviewed studies, relevant regulatory documents, and current supply chain datasets. Scenario-based stress tests validate findings, ensuring accuracy within evolving market environments.

Why This Report Matters

  • Delivers practical, evidence-based intelligence for senior decision-makers involved in commercialization, payer negotiations, and operational management within the MRSA drugs market.
  • Connects key insights to real-world clinical, technological, and market developments, enhancing immediate and future strategic decisions at both local and global levels.
  • Enables informed supply planning and contract management so leaders can effectively navigate tariff implications and streamline distribution for consistent market access.

Conclusion

The MRSA therapeutics market continues to evolve due to clinical advances and ongoing operational challenges. Focusing on differentiation, supply resilience, and payer integration is essential for sustaining value and supporting optimal treatment outcomes in a competitive landscape.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. Market Share Analysis, 2025
3.5. FPNV Positioning Matrix, 2025
3.6. New Revenue Opportunities
3.7. Next-Generation Business Models
3.8. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Porter’s Five Forces Analysis
4.4. PESTLE Analysis
4.5. Market Outlook
4.5.1. Near-Term Market Outlook (0-2 Years)
4.5.2. Medium-Term Market Outlook (3-5 Years)
4.5.3. Long-Term Market Outlook (5-10 Years)
4.6. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of United States Tariffs 2025
7. Cumulative Impact of Artificial Intelligence 2025
8. Methicillin-Resistant Staphylococcus Aureus Drugs Market, by Administration Route
8.1. Intravenous
8.2. Oral
9. Methicillin-Resistant Staphylococcus Aureus Drugs Market, by Patient Type
9.1. Inpatient
9.2. Outpatient
10. Methicillin-Resistant Staphylococcus Aureus Drugs Market, by Drug Class
10.1. Cephalosporins
10.1.1. Ceftaroline
10.2. Glycopeptides
10.2.1. Teicoplanin
10.2.2. Vancomycin
10.3. Lipopeptides
10.3.1. Daptomycin
10.4. Oxazolidinones
10.4.1. Linezolid
10.4.2. Tedizolid
10.5. Tetracyclines
10.5.1. Eravacycline
10.5.2. Tigecycline
11. Methicillin-Resistant Staphylococcus Aureus Drugs Market, by Distribution Channel
11.1. Hospital Pharmacy
11.2. Online Pharmacy
11.3. Retail Pharmacy
12. Methicillin-Resistant Staphylococcus Aureus Drugs Market, by Region
12.1. Americas
12.1.1. North America
12.1.2. Latin America
12.2. Europe, Middle East & Africa
12.2.1. Europe
12.2.2. Middle East
12.2.3. Africa
12.3. Asia-Pacific
13. Methicillin-Resistant Staphylococcus Aureus Drugs Market, by Group
13.1. ASEAN
13.2. GCC
13.3. European Union
13.4. BRICS
13.5. G7
13.6. NATO
14. Methicillin-Resistant Staphylococcus Aureus Drugs Market, by Country
14.1. United States
14.2. Canada
14.3. Mexico
14.4. Brazil
14.5. United Kingdom
14.6. Germany
14.7. France
14.8. Russia
14.9. Italy
14.10. Spain
14.11. China
14.12. India
14.13. Japan
14.14. Australia
14.15. South Korea
15. United States Methicillin-Resistant Staphylococcus Aureus Drugs Market
16. China Methicillin-Resistant Staphylococcus Aureus Drugs Market
17. Competitive Landscape
17.1. Market Concentration Analysis, 2025
17.1.1. Concentration Ratio (CR)
17.1.2. Herfindahl Hirschman Index (HHI)
17.2. Recent Developments & Impact Analysis, 2025
17.3. Product Portfolio Analysis, 2025
17.4. Benchmarking Analysis, 2025
17.5. AbbVie Inc.
17.6. Armata Pharmaceuticals, Inc.
17.7. AstraZeneca PLC
17.8. Basilea Pharmaceutica Ltd.
17.9. Bausch Health Companies Inc.
17.10. Cardinal Health, Inc.
17.11. Cumberland Pharmaceuticals Inc.
17.12. Innovation Pharmaceuticals Inc.
17.13. Johnson & Johnson Services, Inc.
17.14. Merck & Co., Inc.
17.15. Novartis AG
17.16. Paratek Pharmaceuticals, Inc.
17.17. Pfizer Inc.
17.18. Takeda Pharmaceutical Company Limited
17.19. Teva Pharmaceutical Industries ltd
List of Figures
FIGURE 1. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 2. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 3. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET, FPNV POSITIONING MATRIX, 2025
FIGURE 4. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 5. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY PATIENT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 6. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 7. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 9. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 11. UNITED STATES METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 12. CHINA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
List of Tables
TABLE 1. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 2. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 3. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
TABLE 4. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 5. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 6. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
TABLE 7. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
TABLE 8. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 9. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
TABLE 10. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY INPATIENT, BY REGION, 2018-2032 (USD MILLION)
TABLE 11. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY INPATIENT, BY GROUP, 2018-2032 (USD MILLION)
TABLE 12. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY INPATIENT, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 13. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OUTPATIENT, BY REGION, 2018-2032 (USD MILLION)
TABLE 14. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OUTPATIENT, BY GROUP, 2018-2032 (USD MILLION)
TABLE 15. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OUTPATIENT, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 16. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 17. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY CEPHALOSPORINS, BY REGION, 2018-2032 (USD MILLION)
TABLE 18. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY CEPHALOSPORINS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 19. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY CEPHALOSPORINS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 20. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY CEPHALOSPORINS, 2018-2032 (USD MILLION)
TABLE 21. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY CEFTAROLINE, BY REGION, 2018-2032 (USD MILLION)
TABLE 22. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY CEFTAROLINE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 23. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY CEFTAROLINE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 24. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY GLYCOPEPTIDES, BY REGION, 2018-2032 (USD MILLION)
TABLE 25. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY GLYCOPEPTIDES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 26. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY GLYCOPEPTIDES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 27. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY GLYCOPEPTIDES, 2018-2032 (USD MILLION)
TABLE 28. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY TEICOPLANIN, BY REGION, 2018-2032 (USD MILLION)
TABLE 29. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY TEICOPLANIN, BY GROUP, 2018-2032 (USD MILLION)
TABLE 30. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY TEICOPLANIN, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 31. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY VANCOMYCIN, BY REGION, 2018-2032 (USD MILLION)
TABLE 32. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY VANCOMYCIN, BY GROUP, 2018-2032 (USD MILLION)
TABLE 33. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY VANCOMYCIN, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 34. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY LIPOPEPTIDES, BY REGION, 2018-2032 (USD MILLION)
TABLE 35. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY LIPOPEPTIDES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 36. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY LIPOPEPTIDES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 37. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY LIPOPEPTIDES, 2018-2032 (USD MILLION)
TABLE 38. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DAPTOMYCIN, BY REGION, 2018-2032 (USD MILLION)
TABLE 39. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DAPTOMYCIN, BY GROUP, 2018-2032 (USD MILLION)
TABLE 40. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DAPTOMYCIN, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 41. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OXAZOLIDINONES, BY REGION, 2018-2032 (USD MILLION)
TABLE 42. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OXAZOLIDINONES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 43. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OXAZOLIDINONES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 44. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OXAZOLIDINONES, 2018-2032 (USD MILLION)
TABLE 45. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY LINEZOLID, BY REGION, 2018-2032 (USD MILLION)
TABLE 46. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY LINEZOLID, BY GROUP, 2018-2032 (USD MILLION)
TABLE 47. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY LINEZOLID, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 48. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY TEDIZOLID, BY REGION, 2018-2032 (USD MILLION)
TABLE 49. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY TEDIZOLID, BY GROUP, 2018-2032 (USD MILLION)
TABLE 50. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY TEDIZOLID, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 51. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY TETRACYCLINES, BY REGION, 2018-2032 (USD MILLION)
TABLE 52. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY TETRACYCLINES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 53. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY TETRACYCLINES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 54. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY TETRACYCLINES, 2018-2032 (USD MILLION)
TABLE 55. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ERAVACYCLINE, BY REGION, 2018-2032 (USD MILLION)
TABLE 56. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ERAVACYCLINE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 57. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ERAVACYCLINE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 58. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY TIGECYCLINE, BY REGION, 2018-2032 (USD MILLION)
TABLE 59. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY TIGECYCLINE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 60. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY TIGECYCLINE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 61. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 62. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
TABLE 63. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 64. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 65. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2032 (USD MILLION)
TABLE 66. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 67. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 68. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
TABLE 69. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 70. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 71. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 72. AMERICAS METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 73. AMERICAS METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 74. AMERICAS METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
TABLE 75. AMERICAS METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 76. AMERICAS METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY CEPHALOSPORINS, 2018-2032 (USD MILLION)
TABLE 77. AMERICAS METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY GLYCOPEPTIDES, 2018-2032 (USD MILLION)
TABLE 78. AMERICAS METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY LIPOPEPTIDES, 2018-2032 (USD MILLION)
TABLE 79. AMERICAS METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OXAZOLIDINONES, 2018-2032 (USD MILLION)
TABLE 80. AMERICAS METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY TETRACYCLINES, 2018-2032 (USD MILLION)
TABLE 81. AMERICAS METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 82. NORTH AMERICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 83. NORTH AMERICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 84. NORTH AMERICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
TABLE 85. NORTH AMERICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 86. NORTH AMERICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY CEPHALOSPORINS, 2018-2032 (USD MILLION)
TABLE 87. NORTH AMERICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY GLYCOPEPTIDES, 2018-2032 (USD MILLION)
TABLE 88. NORTH AMERICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY LIPOPEPTIDES, 2018-2032 (USD MILLION)
TABLE 89. NORTH AMERICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OXAZOLIDINONES, 2018-2032 (USD MILLION)
TABLE 90. NORTH AMERICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY TETRACYCLINES, 2018-2032 (USD MILLION)
TABLE 91. NORTH AMERICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 92. LATIN AMERICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 93. LATIN AMERICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 94. LATIN AMERICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
TABLE 95. LATIN AMERICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 96. LATIN AMERICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY CEPHALOSPORINS, 2018-2032 (USD MILLION)
TABLE 97. LATIN AMERICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY GLYCOPEPTIDES, 2018-2032 (USD MILLION)
TABLE 98. LATIN AMERICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY LIPOPEPTIDES, 2018-2032 (USD MILLION)
TABLE 99. LATIN AMERICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OXAZOLIDINONES, 2018-2032 (USD MILLION)
TABLE 100. LATIN AMERICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY TETRACYCLINES, 2018-2032 (USD MILLION)
TABLE 101. LATIN AMERICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 102. EUROPE, MIDDLE EAST & AFRICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 103. EUROPE, MIDDLE EAST & AFRICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 104. EUROPE, MIDDLE EAST & AFRICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
TABLE 105. EUROPE, MIDDLE EAST & AFRICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 106. EUROPE, MIDDLE EAST & AFRICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY CEPHALOSPORINS, 2018-2032 (USD MILLION)
TABLE 107. EUROPE, MIDDLE EAST & AFRICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY GLYCOPEPTIDES, 2018-2032 (USD MILLION)
TABLE 108. EUROPE, MIDDLE EAST & AFRICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY LIPOPEPTIDES, 2018-2032 (USD MILLION)
TABLE 109. EUROPE, MIDDLE EAST & AFRICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OXAZOLIDINONES, 2018-2032 (USD MILLION)
TABLE 110. EUROPE, MIDDLE EAST & AFRICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY TETRACYCLINES, 2018-2032 (USD MILLION)
TABLE 111. EUROPE, MIDDLE EAST & AFRICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 112. EUROPE METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 113. EUROPE METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 114. EUROPE METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
TABLE 115. EUROPE METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 116. EUROPE METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY CEPHALOSPORINS, 2018-2032 (USD MILLION)
TABLE 117. EUROPE METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY GLYCOPEPTIDES, 2018-2032 (USD MILLION)
TABLE 118. EUROPE METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY LIPOPEPTIDES, 2018-2032 (USD MILLION)
TABLE 119. EUROPE METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OXAZOLIDINONES, 2018-2032 (USD MILLION)
TABLE 120. EUROPE METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY TETRACYCLINES, 2018-2032 (USD MILLION)
TABLE 121. EUROPE METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 122. MIDDLE EAST METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 123. MIDDLE EAST METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 124. MIDDLE EAST METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
TABLE 125. MIDDLE EAST METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 126. MIDDLE EAST METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY CEPHALOSPORINS, 2018-2032 (USD MILLION)
TABLE 127. MIDDLE EAST METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY GLYCOPEPTIDES, 2018-2032 (USD MILLION)
TABLE 128. MIDDLE EAST METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY LIPOPEPTIDES, 2018-2032 (USD MILLION)
TABLE 129. MIDDLE EAST METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OXAZOLIDINONES, 2018-2032 (USD MILLION)
TABLE 130. MIDDLE EAST METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY TETRACYCLINES, 2018-2032 (USD MILLION)
TABLE 131. MIDDLE EAST METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 132. AFRICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 133. AFRICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 134. AFRICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
TABLE 135. AFRICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 136. AFRICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY CEPHALOSPORINS, 2018-2032 (USD MILLION)
TABLE 137. AFRICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY GLYCOPEPTIDES, 2018-2032 (USD MILLION)
TABLE 138. AFRICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY LIPOPEPTIDES, 2018-2032 (USD MILLION)
TABLE 139. AFRICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OXAZOLIDINONES, 2018-2032 (USD MILLION)
TABLE 140. AFRICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY TETRACYCLINES, 2018-2032 (USD MILLION)
TABLE 141. AFRICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 142. ASIA-PACIFIC METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 143. ASIA-PACIFIC METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 144. ASIA-PACIFIC METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
TABLE 145. ASIA-PACIFIC METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 146. ASIA-PACIFIC METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY CEPHALOSPORINS, 2018-2032 (USD MILLION)
TABLE 147. ASIA-PACIFIC METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY GLYCOPEPTIDES, 2018-2032 (USD MILLION)
TABLE 148. ASIA-PACIFIC METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY LIPOPEPTIDES, 2018-2032 (USD MILLION)
TABLE 149. ASIA-PACIFIC METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OXAZOLIDINONES, 2018-2032 (USD MILLION)
TABLE 150. ASIA-PACIFIC METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY TETRACYCLINES, 2018-2032 (USD MILLION)
TABLE 151. ASIA-PACIFIC METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 152. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 153. ASEAN METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 154. ASEAN METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 155. ASEAN METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
TABLE 156. ASEAN METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 157. ASEAN METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY CEPHALOSPORINS, 2018-2032 (USD MILLION)
TABLE 158. ASEAN METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY GLYCOPEPTIDES, 2018-2032 (USD MILLION)
TABLE 159. ASEAN METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY LIPOPEPTIDES, 2018-2032 (USD MILLION)
TABLE 160. ASEAN METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OXAZOLIDINONES, 2018-2032 (USD MILLION)
TABLE 161. ASEAN METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY TETRACYCLINES, 2018-2032 (USD MILLION)
TABLE 162. ASEAN METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 163. GCC METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 164. GCC METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 165. GCC METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
TABLE 166. GCC METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 167. GCC METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY CEPHALOSPORINS, 2018-2032 (USD MILLION)
TABLE 168. GCC METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY GLYCOPEPTIDES, 2018-2032 (USD MILLION)
TABLE 169. GCC METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY LIPOPEPTIDES, 2018-2032 (USD MILLION)
TABLE 170. GCC METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OXAZOLIDINONES, 2018-2032 (USD MILLION)
TABLE 171. GCC METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY TETRACYCLINES, 2018-2032 (USD MILLION)
TABLE 172. GCC METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 173. EUROPEAN UNION METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 174. EUROPEAN UNION METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 175. EUROPEAN UNION METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
TABLE 176. EUROPEAN UNION METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 177. EUROPEAN UNION METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY CEPHALOSPORINS, 2018-2032 (USD MILLION)
TABLE 178. EUROPEAN UNION METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY GLYCOPEPTIDES, 2018-2032 (USD MILLION)
TABLE 179. EUROPEAN UNION METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY LIPOPEPTIDES, 2018-2032 (USD MILLION)
TABLE 180. EUROPEAN UNION METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OXAZOLIDINONES, 2018-2032 (USD MILLION)
TABLE 181. EUROPEAN UNION METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY TETRACYCLINES, 2018-2032 (USD MILLION)
TABLE 182. EUROPEAN UNION METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 183. BRICS METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 184. BRICS METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 185. BRICS METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
TABLE 186. BRICS METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 187. BRICS METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY CEPHALOSPORINS, 2018-2032 (USD MILLION)
TABLE 188. BRICS METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY GLYCOPEPTIDES, 2018-2032 (USD MILLION)
TABLE 189. BRICS METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY LIPOPEPTIDES, 2018-2032 (USD MILLION)
TABLE 190. BRICS METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OXAZOLIDINONES, 2018-2032 (USD MILLION)
TABLE 191. BRICS METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY TETRACYCLINES, 2018-2032 (USD MILLION)
TABLE 192. BRICS METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 193. G7 METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 194. G7 METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 195. G7 METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
TABLE 196. G7 METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 197. G7 METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY CEPHALOSPORINS, 2018-2032 (USD MILLION)
TABLE 198. G7 METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY GLYCOPEPTIDES, 2018-2032 (USD MILLION)
TABLE 199. G7 METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY LIPOPEPTIDES, 2018-2032 (USD MILLION)
TABLE 200. G7 METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OXAZOLIDINONES, 2018-2032 (USD MILLION)
TABLE 201. G7 METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY TETRACYCLINES, 2018-2032 (USD MILLION)
TABLE 202. G7 METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 203. NATO METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 204. NATO METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 205. NATO METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
TABLE 206. NATO METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 207. NATO METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY CEPHALOSPORINS, 2018-2032 (USD MILLION)
TABLE 208. NATO METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY GLYCOPEPTIDES, 2018-2032 (USD MILLION)
TABLE 209. NATO METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY LIPOPEPTIDES, 2018-2032 (USD MILLION)
TABLE 210. NATO METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OXAZOLIDINONES, 2018-2032 (USD MILLION)
TABLE 211. NATO METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY TETRACYCLINES, 2018-2032 (USD MILLION)
TABLE 212. NATO METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 213. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 214. UNITED STATES METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 215. UNITED STATES METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 216. UNITED STATES METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
TABLE 217. UNITED STATES METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 218. UNITED STATES METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY CEPHALOSPORINS, 2018-2032 (USD MILLION)
TABLE 219. UNITED STATES METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY GLYCOPEPTIDES, 2018-2032 (USD MILLION)
TABLE 220. UNITED STATES METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY LIPOPEPTIDES, 2018-2032 (USD MILLION)
TABLE 221. UNITED STATES METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OXAZOLIDINONES, 2018-2032 (USD MILLION)
TABLE 222. UNITED STATES METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY TETRACYCLINES, 2018-2032 (USD MILLION)
TABLE 223. UNITED STATES METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 224. CHINA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 225. CHINA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 226. CHINA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
TABLE 227. CHINA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 228. CHINA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY CEPHALOSPORINS, 2018-2032 (USD MILLION)
TABLE 229. CHINA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY GLYCOPEPTIDES, 2018-2032 (USD MILLION)
TABLE 230. CHINA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY LIPOPEPTIDES, 2018-2032 (USD MILLION)
TABLE 231. CHINA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OXAZOLIDINONES, 2018-2032 (USD MILLION)
TABLE 232. CHINA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY TETRACYCLINES, 2018-2032 (USD MILLION)
TABLE 233. CHINA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)

Companies Mentioned

The key companies profiled in this Methicillin-Resistant Staphylococcus Aureus Drugs market report include:
  • AbbVie Inc.
  • Armata Pharmaceuticals, Inc.
  • AstraZeneca PLC
  • Basilea Pharmaceutica Ltd.
  • Bausch Health Companies Inc.
  • Cardinal Health, Inc.
  • Cumberland Pharmaceuticals Inc.
  • Innovation Pharmaceuticals Inc.
  • Johnson & Johnson Services, Inc.
  • Merck & Co., Inc.
  • Novartis AG
  • Paratek Pharmaceuticals, Inc.
  • Pfizer Inc.
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries ltd

Table Information

Report AttributeDetails
No. of Pages197
PublishedJanuary 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 2.47 Billion
Forecasted Market Value ( USD ) by 2032 $ 3.44 Billion
Compound Annual Growth Rate5.7%
Regions CoveredGlobal
No. of Companies Mentioned15

Related Topics

Related Reports

Methicillin-Resistant Staphylococcus Aureus Treatment Market - Global Forecast 2025-2030 - Product Image

Methicillin-Resistant Staphylococcus Aureus Treatment Market - Global Forecast 2025-2030

  • Report
  • 183 Pages
  • Global
From
Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market Report 2025 - Product Image

Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market Report 2025

  • Report
  • 250 Pages
  • Global
From
Methicillin-resistant Staphylococcus Aureus Drugs Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031 - Product Image

Methicillin-resistant Staphylococcus Aureus Drugs Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031

  • Report
  • 185 Pages
  • Global
From
Methicillin-resistant Staphylococcus Aureus (MRSA) Drugs - Global Strategic Business Report - Product Image

Methicillin-resistant Staphylococcus Aureus (MRSA) Drugs - Global Strategic Business Report

  • Report
  • 194 Pages
  • Global
From
Methicillin-Resistant Staphylococcus Aureus Infections - Pipeline Insight, 2025 - Product Image

Methicillin-Resistant Staphylococcus Aureus Infections - Pipeline Insight, 2025

  • Drug Pipelines
  • 100 Pages
  • Global
From

About the MRSA Drug Market

Methicillin-resistant Staphylococcus aureus (MRSA) is a type of bacteria that is resistant to many antibiotics. As a result, it is a major cause of infections in hospitals and other healthcare settings. To combat this, the MRSA drug market has developed a range of treatments, including antibiotics, antiseptics, and vaccines. These drugs are designed to target the bacteria and reduce the risk of infection. The MRSA drug market is highly competitive, with a range of companies offering different treatments. Some of the major players in the market include Pfizer, Merck, GlaxoSmithKline, Sanofi, and Novartis. These companies are constantly developing new treatments to combat the spread of MRSA and other infectious diseases. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.